JCR Pharmaceuticals Co., Ltd. (4552.T)
JPY 610.0
(-0.81%)
JPY 610.0
(-0.81%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 4.54 Billion JPY | -52.28% |
| 2022 | 9.52 Billion JPY | 175.37% |
| 2021 | -12.63 Billion JPY | -54.82% |
| 2020 | -8.16 Billion JPY | -268.23% |
| 2019 | -2.21 Billion JPY | -5.27% |
| 2018 | -2.1 Billion JPY | -331.57% |
| 2017 | 909 Million JPY | 235.55% |
| 2016 | -670.61 Million JPY | -153.86% |
| 2015 | 1.24 Billion JPY | -50.21% |
| 2014 | 2.5 Billion JPY | -22.15% |
| 2013 | 3.21 Billion JPY | -3.55% |
| 2012 | 3.33 Billion JPY | 4.92% |
| 2011 | 3.17 Billion JPY | 19.62% |
| 2010 | 2.65 Billion JPY | -18.5% |
| 2009 | 3.25 Billion JPY | 6.71% |
| 2008 | 3.05 Billion JPY | -24.04% |
| 2007 | 4.01 Billion JPY | -5.95% |
| 2006 | 4.27 Billion JPY | 18.97% |
| 2005 | 3.58 Billion JPY | -37.25% |
| 2004 | 5.71 Billion JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 9.88 Billion JPY | -16.31% |
| 2024 Q2 | 10.14 Billion JPY | -7.99% |
| 2023 Q1 | 7.96 Billion JPY | -16.31% |
| 2023 Q3 | 4.99 Billion JPY | -31.82% |
| 2023 Q2 | 7.33 Billion JPY | -7.99% |
| 2023 Q4 | 4.54 Billion JPY | -9.1% |
| 2023 FY | 4.54 Billion JPY | -52.28% |
| 2022 Q2 | -10 Billion JPY | 32.78% |
| 2022 Q4 | 9.52 Billion JPY | 95.89% |
| 2022 FY | 9.52 Billion JPY | 175.37% |
| 2022 Q1 | -14.88 Billion JPY | -17.84% |
| 2022 Q3 | 4.86 Billion JPY | 148.58% |
| 2021 Q3 | -13.2 Billion JPY | -470.93% |
| 2021 Q4 | -12.63 Billion JPY | 4.3% |
| 2021 FY | -12.63 Billion JPY | -54.82% |
| 2021 Q1 | -6.16 Billion JPY | 24.44% |
| 2021 Q2 | -2.31 Billion JPY | 62.5% |
| 2020 Q1 | -56 Million JPY | 97.47% |
| 2020 Q4 | -8.16 Billion JPY | -168.16% |
| 2020 FY | -8.16 Billion JPY | -268.23% |
| 2020 Q2 | -1.81 Billion JPY | -3132.14% |
| 2020 Q3 | -3.04 Billion JPY | -68.12% |
| 2019 Q1 | -2.58 Billion JPY | -22.99% |
| 2019 FY | -2.21 Billion JPY | -5.27% |
| 2019 Q3 | 1.04 Billion JPY | 178.24% |
| 2019 Q4 | -2.21 Billion JPY | -312.46% |
| 2019 Q2 | -1.33 Billion JPY | 48.51% |
| 2018 Q1 | 166 Million JPY | -81.74% |
| 2018 FY | -2.1 Billion JPY | -331.57% |
| 2018 Q4 | -2.1 Billion JPY | -49.5% |
| 2018 Q3 | -1.4 Billion JPY | 18.28% |
| 2018 Q2 | -1.72 Billion JPY | -1137.95% |
| 2017 Q1 | -1.71 Billion JPY | -156.33% |
| 2017 FY | 909 Million JPY | 235.55% |
| 2017 Q2 | 1.36 Billion JPY | 179.58% |
| 2017 Q4 | 909 Million JPY | -64.64% |
| 2017 Q3 | 2.57 Billion JPY | 87.94% |
| 2016 Q4 | -670.61 Million JPY | -166.98% |
| 2016 FY | -670.61 Million JPY | -153.86% |
| 2016 Q3 | 1 Billion JPY | 232.29% |
| 2016 Q2 | -756.84 Million JPY | -41.84% |
| 2016 Q1 | -533.57 Million JPY | -142.85% |
| 2015 Q3 | 1.09 Billion JPY | -7.25% |
| 2015 Q2 | 1.17 Billion JPY | -11.4% |
| 2015 Q1 | 1.32 Billion JPY | -46.85% |
| 2015 Q4 | 1.24 Billion JPY | 14.01% |
| 2015 FY | 1.24 Billion JPY | -50.21% |
| 2014 FY | 2.5 Billion JPY | -22.15% |
| 2014 Q4 | 2.5 Billion JPY | 92.38% |
| 2014 Q3 | 1.29 Billion JPY | 14.99% |
| 2014 Q2 | 1.13 Billion JPY | -38.99% |
| 2014 Q1 | 1.85 Billion JPY | -42.32% |
| 2013 FY | 3.21 Billion JPY | -3.55% |
| 2013 Q1 | 1.86 Billion JPY | -44.12% |
| 2013 Q2 | 1.88 Billion JPY | 1.07% |
| 2013 Q3 | 1.13 Billion JPY | -39.47% |
| 2013 Q4 | 3.21 Billion JPY | 182.17% |
| 2012 Q2 | 2.2 Billion JPY | 68.7% |
| 2012 Q4 | 3.33 Billion JPY | 67.26% |
| 2012 FY | 3.33 Billion JPY | 4.92% |
| 2012 Q1 | 1.3 Billion JPY | -58.84% |
| 2012 Q3 | 1.99 Billion JPY | -9.67% |
| 2011 FY | 3.17 Billion JPY | 19.62% |
| 2011 Q4 | 3.17 Billion JPY | 161.06% |
| 2011 Q3 | 1.21 Billion JPY | -25.15% |
| 2011 Q2 | 1.62 Billion JPY | 754.29% |
| 2011 Q1 | -248.23 Million JPY | -109.36% |
| 2010 Q3 | 721.57 Million JPY | 72.45% |
| 2010 Q4 | 2.65 Billion JPY | 267.7% |
| 2010 FY | 2.65 Billion JPY | -18.5% |
| 2010 Q1 | 132.03 Million JPY | -95.94% |
| 2010 Q2 | 418.43 Million JPY | 216.92% |
| 2009 FY | 3.25 Billion JPY | 6.71% |
| 2009 Q2 | 2.81 Billion JPY | 0.0% |
| 2009 Q4 | 3.25 Billion JPY | 59.16% |
| 2009 Q3 | 2.04 Billion JPY | -27.24% |
| 2008 Q3 | 2.47 Billion JPY | 0.0% |
| 2008 Q4 | 3.05 Billion JPY | 23.33% |
| 2008 FY | 3.05 Billion JPY | -24.04% |
| 2007 FY | 4.01 Billion JPY | -5.95% |
| 2006 FY | 4.27 Billion JPY | 18.97% |
| 2005 FY | 3.58 Billion JPY | -37.25% |
| 2004 FY | 5.71 Billion JPY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Kyowa Kirin Co., Ltd. | -378.83 Billion JPY | 101.199% |
| Astellas Pharma Inc. | 670.02 Billion JPY | 99.322% |
| Chugai Pharmaceutical Co., Ltd. | -445.21 Billion JPY | 101.021% |
| Ono Pharmaceutical Co., Ltd. | -157.27 Billion JPY | 102.889% |
| Santen Pharmaceutical Co., Ltd. | -59.42 Billion JPY | 107.647% |
| Daiichi Sankyo Company, Limited | -259.26 Billion JPY | 101.753% |
| Otsuka Holdings Co., Ltd. | -299.15 Billion JPY | 101.519% |
| Perseus Proteomics Inc. | -1.54 Billion JPY | 394.793% |